Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Biochemistry

• Publication date

  2004-12-21

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/BI048413QPMID 15595835
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states.

  2004cited by this paper
• Electron crystallography reveals the structure of metarhodopsin I

  2004cited by this paper
• Opioid receptors.

  2004cited by this paper
• Recognition of privileged structures by G-protein coupled receptors.

  2004cited by this paper
• Refinement of a homology model of the mu-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites.

  2004cited by this paper
• Rhodopsin Activation Exposes a Key Hydrophobic Binding Site for the Transducin α-Subunit C Terminus*

  2004cited by this paper
• Opioid receptor random mutagenesis reveals a mechanism for G protein–coupled receptor activation

  2003cited by this paper
• Structure-based analysis of GPCR function: conformational adaptation of both agonist and receptor upon leukotriene B4 binding to recombinant BLT1.

  2003cited by this paper
• Conversion of delta-, kappa- and mu-receptor selective opioid peptide agonists into delta-, kappa- and mu-selective antagonists.

  2003cited by this paper
• Three-dimensional model for meta-II rhodopsin, an activated G-protein-coupled receptor.

  2003cited by this paper
• Identification of an allosteric binding site for Zn2+ on the beta2 adrenergic receptor.

  2003cited by this paper
• High Affinity Agonistic Metal Ion Binding Sites within the Melanocortin 4 Receptor Illustrate Conformational Change of Transmembrane Region 3*

  2003cited by this paper
• Rhodopsin crystal: new template yielding realistic models of G-protein-coupled receptors?

  2003cited by this paper
• The crystallographic model of rhodopsin and its use in studies of other G protein-coupled receptors.

  2003cited by this paper
• Highly conserved serine in the third transmembrane helix of the luteinizing hormone/human chorionic gonadotropin receptor regulates receptor activation.

  2003cited by this paper
• Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking.

  2003cited by this paper
• Activation of G-protein-coupled receptors: a common molecular mechanism.

  2003cited by this paper
• Structural basis for activation of G-protein-coupled receptors.

  2002cited by this paper
• Lessons from constitutively active mutants of G protein-coupled receptors.

  2002cited by this paper
• Structural studies of metarhodopsin II, the activated form of the G-protein coupled receptor, rhodopsin.

  2002cited by this paper
• Conformational Changes That Occur during M3Muscarinic Acetylcholine Receptor Activation Probed by the Use of an in Situ Disulfide Cross-linking Strategy*

  2002cited by this paper
• Development and validation of opioid ligand-receptor interaction models: the structural basis of mu vs delta selectivity.

  2002cited by this paper
• Constitutive activation of the opioid receptor‐like (ORL1) receptor by mutation of Asn133 to tryptophan in the third transmembrane region

  2002cited by this paper
• Crystal structure of rhodopsin: a template for cone visual pigments and other G protein-coupled receptors.

  2002cited by this paper
• Minireview: Insights into G protein-coupled receptor function using molecular models.

  2001cited by this paper
• Functionally Different Agonists Induce Distinct Conformations in the G Protein Coupling Domain of the β2Adrenergic Receptor*

  2001cited by this paper
• Constitutive activation of the mu opioid receptor by mutation of D3.49(164), but not D3.32(147): D3.49(164) is critical for stabilization of the inactive form of the receptor and for its expression.

  2001cited by this paper
• Agonist-induced conformational changes in the G-protein-coupling domain of the β2 adrenergic receptor

  2001cited by this paper
• Structure and function in rhodopsin: mapping light-dependent changes in distance between residue 316 in helix 8 and residues in the sequence 60-75, covering the cytoplasmic end of helices TM1 and TM2 and their connection loop CL1.

  2001cited by this paper
• Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors.

  2001cited by this paper
• Activation of rhodopsin: new insights from structural and biochemical studies.

  2001cited by this paper
• Structure and function in rhodopsin: mapping light-dependent changes in distance between residue 65 in helix TM1 and residues in the sequence 306-319 at the cytoplasmic end of helix TM7 and in helix H8.

  2001cited by this paper
• Functional role of a conserved motif in TM6 of the rat mu opioid receptor: constitutively active and inactive receptors result from substitutions of Thr6.34(279) with Lys and Asp.

  2001cited by this paper
• Receptor activation: what does the rhodopsin structure tell us?

  2001cited by this paper
• Non-alpha-helical elements modulate polytopic membrane protein architecture.

  2001cited by this paper
• Uncovering molecular mechanisms involved in activation of G protein-coupled receptors.

  2000cited by this paper
• Binding of norbinaltorphimine (norBNI) congeners to wild-type and mutant mu and kappa opioid receptors: molecular recognition loci for the pharmacophore and address components of kappa antagonists.

  2000cited by this paper
• The Protein Data Bank

  2000cited by this paper
• Opioid receptors: from genes to mice.

  2000cited by this paper
• Tetrapeptide derivatives of [D-Pen(2),D-Pen(5)]-enkephalin (DPDPE) lacking an N-terminal tyrosine residue are agonists at the mu-opioid receptor.

  2000cited by this paper
• Selectivity of mu-opioid receptor determined by interfacial residues near third extracellular loop.

  2000cited by this paper
• Functional inactivation of the nociceptin receptor by alanine substitution of glutamine 286 at the C terminus of transmembrane segment VI: evidence from a site-directed mutagenesis study of the ORL1 receptor transmembrane-binding domain.

  2000cited by this paper
• Partial agonism through a zinc-Ion switch constructed between transmembrane domains III and VII in the tachykinin NK(1) receptor.

  2000cited by this paper
• Structure and regulation of opioid receptors.

  2000cited by this paper
• G protein-coupled receptor activation: analysis of a highly constrained, "straitjacketed" rhodopsin.

  2000cited by this paper
• Interaction of p-fluorofentanyl on cloned human opioid receptors and exploration of the role of Trp-318 and His-319 in mu-opioid receptor selectivity.

  2000cited by this paper
• Conformational Changes in Rhodopsin

  1999cited by this paper
• Constitutive Activation of the δ Opioid Receptor by Mutations in Transmembrane Domains III and VII*

  1999cited by this paper
• Conversion of agonist site to metal-ion chelator site in the beta(2)-adrenergic receptor.

  1999cited by this paper
• The delta-opioid receptor: molecular pharmacology, signal transduction, and the determination of drug efficacy.

  1999cited by this paper
• Opioid peptide receptor studies, 11: Involvement of Tyr148, Trp318 and His319 of the rat μ‐opioid receptor in binding of μ‐selective ligands

  1999cited by this paper
• Structure and function in rhodopsin: effects of disulfide cross-links in the cytoplasmic face of rhodopsin on transducin activation and phosphorylation by rhodopsin kinase.

  1999cited by this paper
• ASP147 in the third transmembrane helix of the rat mu opioid receptor forms ion-pairing with morphine and naltrexone.

  1999cited by this paper
• Mutation of human mu opioid receptor extracellular "disulfide cysteine" residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane.

  1999cited by this paper
• Mutational analysis of the structure and function of opioid receptors.

  1999cited by this paper
• Tertiary interactions between transmembrane segments 3 and 5 near the cytoplasmic side of rhodopsin.

  1999cited by this paper
• Structural organization of G-protein-coupled receptors

  1999cited by this paper
• Structural features and light-dependent changes in the sequence 59-75 connecting helices I and II in rhodopsin: a site-directed spin-labeling study.

  1999cited by this paper
• Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints.

  1998cited by this paper
• Development of a model for the delta-opioid receptor pharmacophore. 4. Residue 3 dehydrophenylalanine analogues of Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13) confirm required gauche orientation of aromatic side chain.

  1998cited by this paper
• Light-induced exposure of the cytoplasmic end of transmembrane helix seven in rhodopsin.

  1998cited by this paper
• Specific G protein activation and mu-opioid receptor internalization caused by morphine, DAMGO and endomorphin I.

  1998cited by this paper
• Mutagenesis of a Single Amino Acid in the Rat μ‐Opioid Receptor Discriminates Ligand Binding

  1998cited by this paper
• Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.

  1998cited by this paper
• Constitutive activation of opsin by mutation of methionine 257 on transmembrane helix 6.

  1998cited by this paper
• Key Residues Defining the μ‐Opioid Receptor Binding Pocket: A Site‐Directed Mutagenesis Study

  1997cited by this paper
• Agonists induce conformational changes in transmembrane domains III and VI of the β2 adrenoceptor

  1997cited by this paper
• Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid binding cavity.

  1997cited by this paper
• Structural Instability of a Constitutively Active G Protein-coupled Receptor

  1997cited by this paper
• The transmembrane 7-alpha-bundle of rhodopsin: distance geometry calculations with hydrogen bonding constraints.

  1997cited by this paper
• Mutation of a conserved serine in TM4 of opioid receptors confers full agonistic properties to classical antagonists.

  1996cited by this paper
• Determination of the amino acid residue involved in [3H]beta-funaltrexamine covalent binding in the cloned rat mu-opioid receptor.

  1996cited by this paper
• The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site.

  1996cited by this paper
• Studies on inhibition of mu and delta opioid receptor binding by dithiothreitol and N-ethylmaleimide. His223 is critical for mu opioid receptor binding and inactivation by N-ethylmaleimide.

  1996cited by this paper
• Structural features and light-dependent changes in the cytoplasmic interhelical E-F loop region of rhodopsin: a site-directed spin-labeling study.

  1996cited by this paper
• Role of Aromatic Transmembrane Residues of the -Opioid Receptor in Ligand Recognition (*)

  1996cited by this paper
• Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state.

  1996cited by this paper
• Analysis of selective binding epitopes for the kappa-opioid receptor antagonist nor-binaltorphimine.

  1995cited by this paper
• The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores.

  1995cited by this paper
• -mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity.

  1994cited by this paper
• Development of a model for the delta opioid receptor pharmacophore. 2. Conformationally restricted Phe3 replacements in the cyclic delta receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13).

  1994cited by this paper
• Development of a model for the delta opioid receptor pharmacophore. 1. Conformationally restricted Tyr1 replacements in the cyclic delta receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13).

  1994cited by this paper
• Improved efficiency of protein structure calculations from NMR data using the program DIANA with redundant dihedral angle constraints

  1991cited by this paper
• Cyclic, disulfide- and dithioether-containing opioid tetrapeptides: development of a ligand with high delta opioid receptor selectivity and affinity.

  1988cited by this paper
• ORIENTATION OF AROMATIC RESIDUES IN RHODOPSIN. ROTATION OF ONE TRYPTOPHAN UPON THE META I→META II TRANSITION AFTER ILLUMINATION

  1979cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper

• The impact of free radicals on opioid receptors in tissue injury and inflammation: implications for drug design.

  2026cites this paper
• Production of constrained L-cyclo-tetrapeptides by epimerization-resistant direct aminolysis

  2024cites this paper
• Differential interaction patterns of opioid analgesics with µ opioid receptors correlate with ligand-specific voltage sensitivity

  2023influential citation
• Modelling altered signalling of G-protein coupled receptors in inflamed environment to advance drug design

  2021cites this paper
• Structural Assessment of Agonist Efficacy in the μ-Opioid Receptor: Morphine and Fentanyl Elicit Different Activation Patterns

  2021cites this paper
• Differential recognition of opioid analgesics by µ opioid receptors: Predicted interaction patterns correlate with ligand-specific voltage sensitivity

  2021cites this paper
• Kinetic Machine Learning Unravels Ligand-Directed Conformational Change of μ Opioid Receptor

  2017cites this paper
• Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy

  2017cites this paper
• Molecular Docking study of the Complex between Novel β- Amino acid Tripeptides Based Ligands and Μ-opioid Receptor

  2017cites this paper
• Tryptophan-Containing Non-Cationizable Opioid Peptides - a new chemotype with unusual structure and in vivo activity.

  2017cites this paper
• Synthesis of mixed MOR/KOR efficacy cyclic opioid peptide analogs with antinociceptive activity after systemic administration.

  2016cites this paper
• Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Ligands

  2016cites this paper
• Neuropeptides: Metabolism to Bioactive Fragments and the Pharmacology of Their Receptors

  2015cites this paper
• Structural Requirements for CNS Active Opioid Glycopeptides.

  2015cites this paper
• Design, synthesis, pharmacological evaluation and molecular dynamics of β-amino acids morphan-derivatives as novel ligands for opioid receptors.

  2015cites this paper
• Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.

  2015cites this paper
• Ring size in cyclic endomorphin-2 analogs modulates receptor binding affinity and selectivity.

  2015cites this paper
• Unifying family A GPCR theories of activation.

  2014cites this paper
• Biological Activity of Sporolides A and B from Salinispora tropica: in silico Target Prediction Using Ligand‐Based Pharmacophore Mapping and in vitro activity Validation on HIV‐1 Reverse Transcriptase

  2014cites this paper
• Cyclic endomorphin analogs in targeting opioid receptors to achieve pain relief.

  2014cites this paper
• Translation of structure‐activity relationships from cyclic mixed efficacy opioid peptides to linear analogues

  2014cites this paper
• The Use of Peptides Derived from G Protein-Coupled Receptors and Heterotrimeric G Proteins in the Study of their Structures and Functions

  2014cites this paper
• Cyclization in opioid peptides.

  2013cites this paper
• The Mu and Delta Opioid Receptors: Mixed Efficacy Ligands and Receptor Trafficking

  2013cites this paper
• The role of water and sodium ions in the activation of the μ-opioid receptor.

  2013cites this paper
• Rolle des Wassers und der Natriumionen bei der Aktivierung des μ-Opioidrezeptors†

  2013cites this paper
• Computational Protein Design and Molecular Dynamics Simulations: A Study of Membrane Proteins, Small Peptides and Molecular Systems

  2012cites this paper
• Action of Molecular Switches in GPCRs - Theoretical and Experimental Studies

  2012cites this paper
• Modulation of Opioid Receptor Ligand Affinity and Efficacy Using Active and Inactive State Receptor Models

  2012cites this paper
• Strategies to reduce morphine tolerance in cancer : evaluation of the bifunctional opioid UFP-505

  2012cites this paper
• Molecular docking of opiates and opioid peptides, a tool for the design of selective agonists and antagonists, and for the investigation of atypical ligand-receptor interactions.

  2012cites this paper
• Molecular Aspects of Opioid Receptors and Opioid Receptor Painkillers

  2012cites this paper
• Synthesis of Modified Amino Acids and Insertion in Peptides and Mimetics.Structural Aspects and Impact on Biological Activity.

  2012cites this paper
• Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.

  2011cites this paper
• Synthesis, biological evaluation, and automated docking of constrained analogues of the opioid peptide H-Dmt-D-Ala-Phe-Gly-NH₂ using the 4- or 5-methyl substituted 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one scaffold.

  2011cites this paper
• The Inverse Type II β‐Turn on D‐Trp‐Phe, a Pharmacophoric Motif for MOR Agonists

  2011cites this paper
• Investigating interactions between mu and delta opioid receptors using bifunctional peptides

  2011influential citation
• Molecular modeling study of the opioid receptor interactions with series of cyclic deltorphin analogues

  2011cites this paper
• Update 1 of: computational modeling approaches to structure-function analysis of G protein-coupled receptors.

  2011cites this paper
• DEVELOPMENT AND IN VITRO CHARACTERIZATION OF A NOVEL BIFUNCTIONAL MU-AGONIST/DELTA-ANTAGONIST OPIOID TETRAPEPTIDE

  2011cites this paper
• Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization.

  2010cites this paper
• "Carba"-analogues of fentanyl are opioid receptor agonists.

  2010cites this paper
• A novel alternatively spliced isoform of the mu-opioid receptor: functional antagonism

  2010cites this paper
• Computational modeling of constitutively active mutants of GPCRs C5a receptor.

  2010cites this paper
• Conformationally constrained opioid ligands: the Dmt-Aba and Dmt-Aia versus Dmt-Tic scaffold.

  2009cites this paper
• Design, Synthesis and Evaluation of Peptide-Based Affinity Labels for Mu Opioid Receptors

  2009cites this paper
• New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide.

  2009cites this paper
• Functional characterization and structural modeling of obesity associated mutations in the melanocortin 4 receptor.

  2009cites this paper
• Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.

  2009cites this paper
• A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists.

  2008cites this paper
• Improving the Biopharmaceutical Properties of Cyclic Opioid Peptide Prodrugs

  2008cites this paper
• Improved model building and assessment of the Calcium‐sensing receptor transmembrane domain

  2008cites this paper
• Bioinformatic analysis of the origin, sequence and diversification of mu opioid receptors in vertebrates.

  2008cites this paper
• Molecular modeling of the second extracellular loop of G‐protein coupled receptors and its implication on structure‐based virtual screening

  2008cites this paper
• The Full-Length Mu-Opioid Receptor: A Conformational Study by Circular Dichroism in Trifluoroethanol and Membrane-Mimetic Environments

  2008cites this paper
• Investigation of the interaction between the atypical agonist c[YpwFG] and MOR

  2008cites this paper
• Topological exploration of cyclic endomorphin-1 analogues, structurally defined models for investigating the bioactive conformation of MOR agonists.

  2007cites this paper
• Modeling activated states of GPCRs: the rhodopsin template

  2007cites this paper
• Re-discussion of the importance of ionic interactions in stabilizing ligand-opioid receptor complex and in activating signal transduction.

  2007cites this paper
• Conformation of a double-membrane-spanning fragment of a G protein-coupled receptor: effects of hydrophobic environment and pH.

  2007cites this paper
• Molecular Mechanism of the Constitutive Activation of the L250Q Human Melanocortin‐4 Receptor Polymorphism ‡

  2006cites this paper
• Modeling activated states of GPCRs: the rhodopsin template

  2006cites this paper
• Radiolytic protein footprinting with mass spectrometry to probe the structure of macromolecular complexes.

  2006cites this paper
• Design of high affinity cyclic pentapeptide ligands for kappa-opioid receptors.

  2005cites this paper
• Homology modeling of opioid receptor-ligand complexes using experimental constraints

  2005cites this paper
• Computational modeling approaches to structure-function analysis of G protein-coupled receptors.

  2005cites this paper
• Structure of rhodopsin and the metarhodopsin I photointermediate.

  2005cites this paper
• Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the κ‐opioid receptor

  2005cites this paper
• Design of high affinity cyclic pentapeptide ligands for Κ-opioid receptors

  2005cites this paper
• Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists.

  2005cites this paper
• Syntheses, biological evaluation, and molecular modeling of 18F-labeled 4-anilidopiperidines as mu-opioid receptor imaging agents.

  2005cites this paper
• Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa-opioid receptor.

  2005cites this paper
• Computational modeling as a tool for designing ligands and Computational modeling as a tool for designing ligands and receptors receptors

  year unknowncites this paper